Radiation for Lung Cancer: 264 Real Stories

264 stories match lung cancer and radiation. 187 of them mention chemotherapy.

Cancer Stories

Drea, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ROS1 Non-Small Cell Lung Cancer: Drea's Patient Story

Patient Info: Drea, Female, Under 40 | Stage IV

Biomarkers: ROS1-positive

Metastatic Site: bilateral lungs; spine; pelvis; brain

Drea had about 3 years of good response and quality of life on her first ROS1 TKI; after new lesions appeared, a second TKI was keeping disease under control with manageable symptoms.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma: fatal hemoptysis from pulmonary artery pseudoaneurysm after chemoradiotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CEA 62 ng/mL; CA19-9 and neuron-specific enolase within normal limits; no molecular biomarkers reported

Metastatic Site: bone (11th thoracic vertebra)

The patient died from airway obstruction after massive hemoptysis caused by rupture of a pulmonary artery pseudoaneurysm that developed at the tumor-invaded pulmonary artery site after chemoradiotherapy.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

EGFR L858R lung adenocarcinoma presenting as rectal and peritoneal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Rectal/peritoneal tumors supported lung origin. Key result: EGFR L858R with TP53 mutations; no other actionable lung alteration reported.

Metastatic Site: rectum; peritoneum; omentum; mesentery; colonic wall

After transverse colostomy and confirmation of EGFR L858R-mutant lung adenocarcinoma metastasis, aumolertinib led to clinical stabilization; palliative radiotherapy was later given to the rectal lesion, but long-term follow-up was not yet available.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA lung adenocarcinoma: complete metabolic remission after chemoradiotherapy, complicated by radiation esophagitis

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: No molecular biomarkers reported

The primary lung lesion achieved complete metabolic remission after concurrent chemoradiotherapy, and radiation esophagitis/stricture improved with conservative management until swallowing returned to a normal diet by 16 months.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung adenocarcinoma with paraneoplastic nephrotic syndrome during pembrolizumab therapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >50% by Roche SP263 assay; KRAS exon 3 mutation; NGS/FISH did not identify targets for first-line targeted therapy

Metastatic Site: brain, bone

Pembrolizumab produced partial response and improved nephrotic-syndrome parameters, but bone metastases progressed in September 2022 and the right upper-lobe target lesion progressed 2 months later, leading to carboplatin plus pemetrexed.

PubMed Central
OutcomeSetback / Progression
Emily, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Emily's Patient Story

Patient Info: Emily, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Right lung; right 8th rib; sacrum; pancreas; brain

Emily had Stage IV EGFR-mutated lung cancer treated with daily targeted therapy, 4 rounds of chemotherapy, and later radiation. As of September 2025, she felt well and described being almost/basically in remission, but her cancer remained treatable rather than curable and she continued daily targeted therapy.

The Patient Story
OutcomeResponding Well
Shauna, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Shauna's Patient Story

Patient Info: Shauna, Female, 50s | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Both lungs

Shauna had Stage IV ALK-positive lung cancer involving both lungs. She was stable for about 5 years on her first TKI, had radiation for limited lung growth, and later switched to a newer TKI with stable scans. She explicitly said she had never had no evidence of disease, so the record should not be labeled NED.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Extensive-stage small-cell lung cancer with immune-related diabetes and stable disease at 2 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor PD-L1 not reported. Immune-related diabetes showed very low C-peptide and negative diabetes autoantibodies; thyroiditis also occurred.

Metastatic Site: pancreas; pleura/pleural effusion; mediastinal lymph…

Two years after the SCLC diagnosis, she was alive with stable oncologic disease after later brain metastases were treated with whole-brain radiotherapy, and she remained insulin-dependent.

PubMed Central
OutcomeLiving With Cancer
Allison, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ALK Lung Adenocarcinoma: Allison's Patient Story

Patient Info: Allison, Female, 40s | Stage IV

Biomarkers: ALK-positive fusion; later ALK resistance mutations reported

Metastatic Site: Bone (spine, femur, ribs, shoulder); brain

Allison was living with Stage IV ALK-positive lung cancer and had a strong response to targeted therapy: brain lesions cleared, most PET activity resolved, and the primary tumor shrank to about 1.5 cm. As of August 2025, she remained on second-line targeted therapy.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

ROS1-rearranged Stage IV lung adenocarcinoma: sequential targeted therapy and 73-month survival

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: CD74-ROS1 C6:R33 fusion; CTNNB1 p.Thr41Ala; APC p.Glu601fs; acquired ROS1 resistance mutation; mTOR p. mutation; FGFR3 gene amplification

Metastatic Site: contralateral lung nodules, brain, pleura

She died on October 6, 2024, after sequential crizotinib, lorlatinib, and cabozantinib for Stage IV ROS1-rearranged lung adenocarcinoma, with total overall survival of 73 months from diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Stage IV Lung Cancer Treated After Osimertinib-Related Lung Toxicity

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; later EGFR T790M resistance mutation

Metastatic Site: brain, lungs, bones, left adrenal gland, meninges

The latest documented treatment was a lower-dose osimertinib rechallenge with corticosteroids, which reduced the tumor without recurrence of the prior interstitial lung disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IVA lung cancer with small-cell and adenocarcinoma components: mixed response before infection halted treatment

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 <1%

Metastatic Site: bone (C2, T10, sacral vertebrae); malignant pleural…

The lung cancer showed mixed responses, with right-lung small-cell progression after chemotherapy/immunotherapy and later treatment interruption because of severe lung infection and respiratory failure.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Man in his 80s with Stage IA1 lung cancer treated with adapted SBRT

Patient Info: Anonymized, Male

Biomarkers: CEA and CA19-9 not elevated; molecular biomarkers not reported

At 1 year after SBRT, CT showed radiation fibrosis and complete metabolic response, with no enlarging mass suggesting local recurrence; ongoing follow-up continued.

PubMed Central
OutcomeCancer-Free / NED
Clara, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: Biomarker found but specific mutation not stated

Metastatic Site: Bone and joints; brain; liver/other organs

Clara was living with Stage IV metastatic lung cancer involving bone/joints, brain, and other organs. As of August 2025, she had received brain radiation and first-line chemotherapy plus immunotherapy, with ongoing lifelong immunotherapy planned.

The Patient Story
OutcomeLiving With Cancer
Jenny, who was diagnosed with Lung CancerLung Cancer

Lung Cancer: Jenny's Patient Story

Patient Info: Jenny, Female

Jenny died from lung cancer in November 2023. As of August 2025, her husband Kyle was raising their children, continuing her advocacy around lung cancer awareness, and preserving her legacy.

The Patient Story
OutcomeIn Memory
Kristen, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IV Small Cell Lung Cancer: Kristen's Patient Story

Patient Info: Kristen, Female | Stage IV

Metastatic Site: liver, abdominal wall, bone

Kristen had metastatic small cell lung cancer with liver, abdominal wall, and bone involvement. As of July 2025, she had completed chemotherapy, had organ-tumor shrinkage, had immunotherapy on hold because of shortness of breath, and was planning bone-directed treatment and possible immunotherapy restart.

The Patient Story
OutcomeCare Ongoing